Refractory Acute Lymphocytic Leukemia
Showing 26 - 50 of >10,000
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Aurora, Seattle (drug, procedure,
Active, not recruiting
- Acute Biphenotypic Leukemia
- +18 more
- Cyclophosphamide
- +8 more
-
Aurora, Colorado
- +2 more
Dec 28, 2022
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,
Recruiting
- Colorectal Cancer
- +11 more
- Vactosertib
- +4 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 18, 2023
Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial (PACE CART19)
Withdrawn
- Acute Lymphoblastic Leukemia
- +2 more
- PACE CART19
- (no location specified)
Mar 9, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia Trial in Boston (Antithymocyte Globulin,
Active, not recruiting
- Acute Myeloid Leukemia
- +6 more
- Antithymocyte Globulin
- Clofarabine
-
Boston, Massachusetts
- +1 more
Jan 25, 2022
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) Trial in United States (voruciclib
Recruiting
- Follicular Lymphoma (FL)
- +6 more
- voruciclib monotherapy
- voruciclib and venetoclax
-
Duarte, California
- +10 more
Aug 10, 2022
Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in Indianapolis (Fludarabine, Total Marrow
Terminated
- Acute Myeloid Leukemia
- +3 more
- Fludarabine
- Total Marrow Irradiation (TMI)
-
Indianapolis, IndianaIndiana University Melvin & Bren Simon Cancer Center
Feb 22, 2022
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Minneapolis (HSCT with TBI Regimen, HSCT with
Recruiting
- Acute Leukemia
- +27 more
- HSCT with TBI Regimen
- HSCT with Non-TBI Regimen
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Apr 12, 2022
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute Trial in Japan, United States (DSP-5336)
Recruiting
- Leukemia, Myeloid, Acute
- Leukemia, Lymphocytic, Acute
-
Houston, Texas
- +5 more
May 31, 2022
Leukemia Trial in Duarte (drug, procedure, radiation)
Active, not recruiting
- Leukemia
- cyclophosphamide
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 17, 2022
Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle
Terminated
- Hematopoietic and Lymphoid Cell Neoplasm
- +12 more
- Laboratory Biomarker Analysis
- ROR1 CAR-specific Autologous T-Lymphocytes
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 11, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +36 more
- Cyclophosphamide
- +4 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 23, 2023
B Cell Leukemias, B Cell Lymphomas Trial in Philadelphia (CART22 cells transduced with a lentiviral vector to express anti-CD22
Recruiting
- B Cell Leukemias
- B Cell Lymphomas
- CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 19, 2022
Acute T-Lymphocytic Leukemia Trial in Suzhou (Venetoclax combined with azacitidine regimen)
Recruiting
- Acute T-Lymphocytic Leukemia
- Venetoclax combined with azacitidine regimen
-
Suzhou, Jiangsu, ChinaThe First Affliated Hospital of Soochow University
Nov 25, 2021
Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in
Completed
- Relapsed or Refractory Haematological Malignancies Including
- +10 more
-
Aachen, Germany
- +11 more
Oct 21, 2021
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic
Terminated
- B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
- +16 more
- Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 28, 2021
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia
- +125 more
- tetanus-CMV fusion peptide vaccine
- laboratory biomarker analysis
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 28, 2022
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult Trial in Orange (Pitavastatin, Venetoclax)
Recruiting
- Acute Myeloid Leukemia
- +5 more
-
Orange, CaliforniaChao Family Comprehensive Cancer Center, University of Californi
Mar 25, 2021
Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)
Not yet recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia
-
Tianjin, Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital, Chinese Aca
Jul 13, 2023
Blastic Plasmacytoid Dendritic Cell Tumor, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in Worldwide (IMGN632)
Recruiting
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- +3 more
-
Gilbert, Arizona
- +14 more
Apr 20, 2022
Leukemia, Acute Lymphocytic (ALL), Leukemia, Acute Myelogenous (AML), MDS Trial in Guangzhou (Chimeric antigen receptor T cells,
Recruiting
- Leukemia, Acute Lymphocytic (ALL)
- +2 more
- Chimeric antigen receptor T cells
- peptide specific dendritic cell
-
Guangzhou, Guangdong, ChinaZhujiang Hospital, Southern Medical University
Aug 1, 2021
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Active, not recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
-
Duarte, California
- +2 more
Oct 7, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Zhengzhou, Nanjing (TQB3909 tablet)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- TQB3909 tablet
-
Zhengzhou, Henan, China
- +1 more
Jul 17, 2023